Dexamethasone sodium phosphate is under clinical development by Scilex Holding and currently in Phase III for Back Pain. According to GlobalData, Phase III drugs for Back Pain have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dexamethasone sodium phosphate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dexamethasone sodium phosphate overview

Dexamethasone sodium phosphate (SEMDEXA) is under development for the treatment of Lumbosacral radicular pain (a type of chronic low back pain) and sciatica. The drug candidate is administered through epidural route. It is formulated as a gel. The drug candidate is a non-opioid steroid injectable without surfactants, preservatives or particulates.

Scilex Holding overview

Scilex Holding (Scilex), a subsidiary of Sorrento Therapeutics Inc, is a pharmaceutical manufacturing company. The company specializes in development and commercialization of non-opioid therapeutic pain management products for the treatment of gout in adults and oral solution for the acute treatment of migraine in adults. Its drug product portfolio includes ZTLido, Gloperba, and Elyxyb. The company service offerings include preclinical research, clinical trials, research and development, drug development, and drug discovery programs. Scilex is headquartered in Palo Alto, California, the US.

For a complete picture of Dexamethasone sodium phosphate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.